Please try another search
Indo Us Bio-Tech Limited reported earnings results for the fourth quarter ended March 31, 2024. For the fourth quarter, the company reported sales was INR 157.66 million compared to INR 181.1 million a year ago. Revenue was INR 159.77 million compared to INR 181.27 million a year ago. Net income was INR 5.24 million compared to INR 27.72 million a year ago. Basic earnings per share from continuing operations was INR 0.26 compared to INR 2.76 a year ago. Diluted earnings per share from continuing operations was INR 0.26 compared to INR 2.76 a year ago.
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Revenue | 157.66 | 221.14 | 158.14 | 174.78 |
Gross Profit | 60.56 | 67.14 | 58.85 | 53.47 |
Operating Income | 9.84 | 41.27 | 23.83 | 26.01 |
Net Income | 5.24 | 36.85 | 16.69 | 20.21 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Assets | 844.56 | |||
Total Liabilities | 217.09 | |||
Total Equity | 627.47 | 544.96 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | ||||
Cash From Investing Activities | ||||
Cash From Financing Activities | ||||
Net Change in Cash |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review